Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies

Annual Review of Public Health

Volumn 23, Issue , 2002, Pages 377-401

  Briggs, Andrew H ^a   O'Brien, Bernie J ^a   Blackhouse, Gordon ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acceptability curves; Confidence intervals; Health economics; Net benefit; Power Sample size

Indexed keywords

BAYES THEOREM; COST EFFECTIVENESS ANALYSIS; EXPERIMENTAL DESIGN; HEALTH ECONOMICS; PRIORITY JOURNAL; PROBABILITY; REVIEW; SAMPLING; STATISTICAL ANALYSIS;

BAYES THEOREM; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; HUMANS; UNCERTAINTY;

EID: 0036246479     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.23.100901.140534     Document Type: Review

References (55)

1. Sample size calculation in economic evaluations
2. Absence of evidence is not evidence of absence
3. Estimating medical costs with censored data
4. The CE plane: A graphic representation of cost-effectiveness
5. Bayesians and frequentists
6. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
7. Power and sample size calculations for stochastic cost-effectiveness analysis
8. The distribution of health care costs and their statistical analysis for economic evaluation
9. A Bayesian approach to stochastic cost-effectiveness analysis
10. Constructing confidence intervals for cost-effectiveness ratios: An evaluation of parametric and nonparametric techniques using Monte Carlo simulation
11. The death of cost-minimisation analysis?
12. Pulling cost-effectiveness analysis up by its bootstraps: A nonparametric approach to confidence interval estimation
13. A regression-based method for estimating mean treatment cost in the presence of right-censoring
14. Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial
15. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies
16. An economic approach to clinical trial design and research priority-setting
17. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews
18. On the use of survival analysis techniques to estimate medical care costs
19. Modelling programme costs in economic evaluation
20. The analysis of censored treatment cost data in economic evaluation
21. Some problems in interval estimation
22. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials
23. On estimating costs for economic evaluation in failure time studies
24. Fieller's method and net health benefits
25. Bayesian estimation of cost-effectiveness ratios from clinical trials
26. Something old, something new, something borrowed, something BLUE: A framework for the marriage of health econometrics and cost-effectiveness analysis
27. Linear regression analysis of censored medical costs
28. Estimating medical costs from incomplete follow-up data
29. Predicting the cost of illness: A comparison of alternative models applied to stroke
30. Definition, interpretation and calculation of cost-effectiveness acceptability curves
31. Redefining the analytical approach to pharmacoeconomics
32. The importance of the normality assumption in large public health data sets
33. Estimating log models: To transform or not to transform?
34. Much ado about two: Reconsidering retransformation and the two-part model in health econometrics
35. Cost-effectiveness of the implantable cardioverter-defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS)
36. Statistical versus quantitative significance in the socioeconomic evaluation of medicines
37. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care
38. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio
39. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy
40. A consumer's guide to subgroup analyses
41. Confidence intervals for cost-effectiveness ratios: A comparison of four methods
42. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetic patients (HDS7): UKPDS 40
43. Design issues for conducting cost-effectiveness analyses alongside clinical trials
44. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals
45. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study
46. The negative side of cost-effectiveness analysis
47. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
48. A note on confidence intervals in cost-effectiveness analysis
49. Costs, effects and C/E-ratios alongside a clinical trial
50. Incremental net benefit in randomized clinical trials
51. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem